Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 5
2003 6
2004 3
2005 7
2006 4
2007 3
2008 3
2009 2
2010 6
2011 6
2012 4
2013 7
2014 5
2015 4
2016 5
2017 9
2018 7
2019 5
2020 5
2021 7
2022 3
2023 3
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes.
Guardiola M, Rehues P, Amigó N, Arrieta F, Botana M, Gimeno-Orna JA, Girona J, Martínez-Montoro JI, Ortega E, Pérez-Pérez A, Sánchez-Margalet V, Pedro-Botet J, Ribalta J; Cardiovascular Disease Group of the Spanish Society of Diabetes. Guardiola M, et al. Eur J Clin Invest. 2024 Aug;54(8):e14214. doi: 10.1111/eci.14214. Epub 2024 Apr 13. Eur J Clin Invest. 2024. PMID: 38613414 Review.
Despite this, cholesterol accumulates in their arteries, in part, due to persistent atherogenic dyslipidaemia characterized by elevated triglycerides, remnant cholesterol, smaller LDL particles and reduced HDL cholesterol. ...
Despite this, cholesterol accumulates in their arteries, in part, due to persistent atherogenic dyslipidaemia characterized by elevat …
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
Averna M, Stroes E; lipid alterations beyond LDL expert working group. Averna M, et al. Atheroscler Suppl. 2017 Apr;26:16-24. doi: 10.1016/S1567-5688(17)30021-1. Atheroscler Suppl. 2017. PMID: 28434480 Review.
METHODS: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a number of other diseases. The recomme …
METHODS: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients …
Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.
Alves M, Fernandes MA, Bahat G, Benetos A, Clemente H, Grodzicki T, Martínez-Sellés M, Mattace-Raso F, Rajkumar C, Ungar A, Werner N, Strandberg TE; EuGMS Special Interest Group inCardiovascular Medicine (Chairpersons A. Ungar and A. Benetos). Alves M, et al. Eur Geriatr Med. 2021 Aug;12(4):725-739. doi: 10.1007/s41999-021-00504-5. Epub 2021 May 25. Eur Geriatr Med. 2021. PMID: 34031865 Free PMC article. Review.
RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins. CONCLUSIONS: Most current cardiovascular drugs can be safely continued during COVID-19. ...
RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins …
Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study.
Climent E, Millán J, Ascaso JF, Suárez-Tembra M, Morillas C, Civeira F, Bellón JM, Pedro-Botet J; Spanish Atherosclerosis Society Working Group on Atherogenic Dyslipidaemia. Climent E, et al. Lipids. 2023 Jul;58(4):197-206. doi: 10.1002/lipd.12374. Epub 2023 Jun 8. Lipids. 2023. PMID: 37291984
Extremely variable prevalence rates of atherogenic dyslipidaemia (AD) in type 2 diabetes (T2DM) subjects have been reported. The primary aim was to assess AD prevalence in Spanish T2DM subjects. ...AD prevalence varied in different age groups and appeared to be more preval …
Extremely variable prevalence rates of atherogenic dyslipidaemia (AD) in type 2 diabetes (T2DM) subjects have been reported. The prim …
Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies.
Di Minno MN, Ambrosino P, Peluso R, Di Minno A, Lupoli R, Dentali F; CaRRDs Study Group. Di Minno MN, et al. Ann Med. 2014 Mar;46(2):73-83. doi: 10.3109/07853890.2013.874661. Epub 2014 Jan 27. Ann Med. 2014. PMID: 24460516 Free article. Review.
BACKGROUND: Some studies showed an anti-atherogenic effect of TNF-alpha blockers on lipid profile, but these data have been challenged. ...METHODS: Prospective studies on rheumatic patients receiving TNF-alpha blockers and providing before-and-after treatment values of tri …
BACKGROUND: Some studies showed an anti-atherogenic effect of TNF-alpha blockers on lipid profile, but these data have been challenge …
Early life infection and proinflammatory, atherogenic metabolomic and lipidomic profiles in infancy: a population-based cohort study.
Mansell T, Saffery R, Burugupalli S, Ponsonby AL, Tang MLK, O'Hely M, Bekkering S, Smith AAT, Rowland R, Ranganathan S, Sly PD, Vuillermin P, Collier F, Meikle P, Burgner D; Barwon Infant Study Investigator Group. Mansell T, et al. Elife. 2022 May 10;11:e75170. doi: 10.7554/eLife.75170. Elife. 2022. PMID: 35535496 Free PMC article.
Low HDL and high triglycerides predict COVID-19 severity.
Masana L, Correig E, Ibarretxe D, Anoro E, Arroyo JA, Jericó C, Guerrero C, Miret M, Näf S, Pardo A, Perea V, Pérez-Bernalte R, Plana N, Ramírez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J; STACOV-XULA research group. Masana L, et al. Sci Rep. 2021 Mar 30;11(1):7217. doi: 10.1038/s41598-021-86747-5. Sci Rep. 2021. PMID: 33785815 Free PMC article.
HDL cholesterol and triglyceride concentrations were correlated with ferritin and D-dimer levels but not with CRP levels. The presence of atherogenic dyslipidaemia during the infection was strongly and independently associated with a worse COVID-19 infection prognosis. ...
HDL cholesterol and triglyceride concentrations were correlated with ferritin and D-dimer levels but not with CRP levels. The presence of …
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.
Cardiometabolic Risk Working Group: Executive Committee; Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E. Cardiometabolic Risk Working Group: Executive Committee, et al. Can J Cardiol. 2011 Mar-Apr;27(2):e1-e33. doi: 10.1016/j.cjca.2010.12.054. Can J Cardiol. 2011. PMID: 21459257 Review.
The concepts of "cardiometabolic risk," "metabolic syndrome," and "risk stratification" overlap and relate to the atherogenic process and development of type 2 diabetes. There is confusion about what these terms mean and how they can best be used to improve our understandi …
The concepts of "cardiometabolic risk," "metabolic syndrome," and "risk stratification" overlap and relate to the atherogenic process …
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group. Ishibashi S, et al. Atherosclerosis. 2016 Jun;249:36-43. doi: 10.1016/j.atherosclerosis.2016.02.029. Epub 2016 Feb 26. Atherosclerosis. 2016. PMID: 27062408 Free article. Clinical Trial.
CONCLUSION: In dyslipidaemic patients with high TG and low HDL-C, K-877 improved TG, HDL-C, and other lipid parameters without increasing AEs or ADRs, compared to placebo and fenofibrate. K-877 can be expected to improve atherogenicity and to be a new beneficial treatment …
CONCLUSION: In dyslipidaemic patients with high TG and low HDL-C, K-877 improved TG, HDL-C, and other lipid parameters without increasing AE …
99 results